Tirzepatide Germany: import rules explained

The question 'can I import tirzepatide into Germany?' has a different shape than the same question asked about most peptides. Tirzepatide is not an unauthorised compound sitting in a regulatory grey zone. It holds a full EU marketing authorisation as Mounjaro^[1], granted by the European Medicines Agency on 15 September 2022 under the centralised procedure. That means it is already legally available in Germany through ordinary prescription channels. The import question therefore turns on a narrower problem: what happens if you try to bring in foreign-labelled versions, buy from online sources outside the EU, or otherwise go around the normal supply chain.

This article sets out tirzepatide's legal status in Germany, how German law governs medicine imports under the Arzneimittelgesetz (AMG), what the rules say about bringing prescription medicines in from outside the EU, and what the grey-market reality looks like without endorsing it. It is not legal or medical advice. If your situation has real legal or health consequences, speak to a German doctor and, if needed, a German lawyer.

Tirzepatide's status in Germany

Tirzepatide is a dual GLP-1 and GIP receptor agonist manufactured by Eli Lilly. In the EU it is marketed under the brand name Mounjaro. The EMA's centralised marketing authorisation^[1] covers two indications for adult patients: type 2 diabetes mellitus (as an adjunct to diet and exercise, including as monotherapy when metformin is not tolerated) and weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea. The marketing authorisation holder is Eli Lilly Nederland B.V.

Because the EMA used the centralised procedure, the authorisation is valid in all EU and EEA member states including Germany. German law, specifically AMG § 21^[3], requires that any finished medicinal product placed on the German market holds either a national authorisation from BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) or an EMA authorisation under EU Regulation 726/2004. Mounjaro satisfies the second route. No separate German-only authorisation is needed.

Tirzepatide is prescription-only (verschreibungspflichtig) in Germany. It cannot be purchased over the counter at a pharmacy; a valid prescription from a licensed prescriber is required. There is no legal pathway for a consumer to obtain it without going through a healthcare professional.

How tirzepatide is legally obtained in Germany

The straightforward route is through the German healthcare system. A physician licensed in Germany assesses the patient, determines that tirzepatide is clinically appropriate, and issues a prescription. The patient then fills the prescription at a licensed German pharmacy. Pharmacies can dispense both the diabetes indication and the weight-management indication, subject to the prescriber's clinical judgment and the applicable reimbursement rules under the statutory health insurance scheme (GKV).

Supply availability has varied since launch, as it has across the EU. When a specific dose or pen configuration is temporarily unavailable, the pharmacist may substitute within the authorised product range or advise the prescriber to adjust the prescription. These supply constraints are a logistics issue, not a legal barrier to access.

Private (Kassenärztliche Vereinigung-independent) prescriptions are also valid. A doctor in a private practice, or a doctor treating a patient privately rather than through GKV, can prescribe Mounjaro and the patient pays out of pocket for the dispensed product. The product dispensed through that route is the same EU-authorised Mounjaro supplied by licensed German pharmacies.

Can you import tirzepatide from outside the EU?

Section 73(1) of the AMG^[2] sets the general rule: medicines that require marketing authorisation may not enter Germany unless they are authorised, registered, or fall within one of the statutory exemptions. The fact that tirzepatide is authorised in Germany does not mean that every tirzepatide-containing product from every country is automatically permissible. The authorisation applies to the specific product Mounjaro, in the specific presentation approved by the EMA, supplied through licensed channels.

The personal-use traveller exception in AMG § 73(2)(6)^[2] allows a person physically crossing the German border to carry medicines in quantities matching their 'usual personal needs' (üblichen persönlichen Bedarf). For an authorised prescription medicine, this does not mean you can buy tirzepatide at a foreign pharmacy and bring it home without a prescription. The product must be lawfully prescribed to you, and you must hold a valid prescription for it. A German doctor's prescription covers Mounjaro dispensed by a German pharmacy; it does not automatically authorise you to substitute a foreign-labelled or non-EU version.

Postal imports of prescription medicines from outside the EU to a private address are not permitted under German law. Tirzepatide bought from an online vendor based in the US, the UK, China, or any non-EU country and shipped to a German address is not covered by any personal-use exemption. The product has no German dispensing prescription attached to it. Customs (Zollverwaltung) can detain and seize such shipments, and the importer has no legal basis to contest the seizure for a prescription medicine arriving without a prescription.

Parallel imports within the EU

Within the EU, parallel imports of medicines are a tightly regulated channel, but it is not a consumer-facing channel. A parallel import means a licensed wholesaler or pharmacy imports an authorised medicine from one EU member state where it is sold at a lower price and relabels it for sale in a higher-price member state. BfArM oversees the parallel import authorisation process for Germany. The product must be the same medicine (same active substance, same pharmaceutical form, same strength) as an already-authorised product in Germany. The parallel importer must hold its own authorisation from BfArM and comply with German packaging and labelling requirements.

This is not a route available to individual consumers. You cannot buy Mounjaro from a French or Polish online pharmacy and have it shipped to your German address as a parallel import. The parallel import framework applies to licensed trade intermediaries operating within a regulated supply chain, not to personal purchases.

Grey-market reality

Grey-market demand for tirzepatide in Germany exists for two main reasons: cost and access speed. Mounjaro's GKV reimbursement for the weight-management indication has been subject to ongoing negotiations between Eli Lilly and the German statutory health insurance system. Patients who cannot get the drug reimbursed through GKV, or who have private prescriptions at full cost, may look for cheaper foreign-sourced alternatives. Supply shortages in certain pen configurations have also pushed some patients to look at non-standard sources.

A share of individual online orders from outside the EU passes through German customs without interception. Stating that observable reality is not an endorsement of it. Volume-based inspection capacity means that not every parcel gets screened. The inconsistency is not legal tolerance; it reflects the limits of customs throughput relative to international parcel traffic.

The legal exposure for a private buyer is different from the exposure for a supply-chain intermediary. German authorities have prosecuted grey-market medicine suppliers, not individual patients purchasing single personal-quantity shipments, in the majority of enforcement actions. But the import itself is not lawful regardless of enforcement statistics, and the risks are not zero. A detained parcel is not returned. Customs may generate an administrative inquiry. Products from unverified sources also carry quality and authenticity risks that do not exist when purchasing from a licensed German pharmacy: no temperature-controlled supply chain, no pharmacovigilance reporting, no recourse if the product is counterfeit or degraded.

Tirzepatide is not a controlled substance under the Betäubungsmittelgesetz (BtMG, Narcotics Act). The relevant legal framework for a private importer is the AMG and customs law, not the narcotics framework. That distinction affects the type of potential legal consequence, not whether importing without a valid prescription is lawful. It is not.

What we do not yet know

GKV reimbursement terms for the obesity indication are subject to ongoing AMNOG benefit assessment negotiations. The outcome affects patient cost and may influence whether access through normal prescription channels becomes easier or harder over the next one to two years. Customs screening patterns change with enforcement priorities. This article reflects the regulatory framework as of July 2026; check with BfArM or a German prescriber for current availability and reimbursement status.

For a broader treatment of tirzepatide's mechanism, clinical evidence, and cross-country regulatory picture, see the tirzepatide overview page. For detail on where tirzepatide sits in the GLP-1 class, including semaglutide comparisons, see tirzepatide regulation by country. For comparable analysis of other prescription medicines and their German import status, see the Germany country page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tirzepatide (Mounjaro) is a prescription-only medicine in Germany. Always consult a qualified healthcare professional before starting any medication. PeptideMethods.com does not sell, distribute, or facilitate the sale of any pharmaceutical product.

Regulatory disclaimer: This page reflects our understanding of German regulatory status as of 2026-07-07. Regulations change. Verify current requirements with BfArM or a qualified German lawyer before making any decision. PeptideMethods.com is not a law firm and does not provide legal advice.